FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to laboratory diagnostics, and can be used for diagnosis of genetically caused essential hypertension. A patient’s blood sample is taken and analysed for BASP1 protein. If the BASP1 protein level in the test blood sample exceeds that of the patient’s blood sample with normal blood pressure, genetically caused essential hypertension is diagnosed.
EFFECT: method provides diagnosing genetically caused essential hypertension ensured by measuring the high BASP1 protein level in the blood sample.
3 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION | 2011 |
|
RU2571284C2 |
| METHOD OF EARLY DIAGNOSTICS OF VARIOUS FORMS OF ESSENTIAL ARTERIAL HYPERTENSION IN CHILDREN AND ADOLESCENTS | 2016 |
|
RU2648453C1 |
| AGENT FOR TREATING PULMONARY HYPERTENSION | 2023 |
|
RU2813890C1 |
| COMPOSITION POSSESSING ENDOTHELIAL PROTECTIVE, VASODILATING AND ANGIOPROTECTIVE EFFECT | 2011 |
|
RU2464019C1 |
| COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASE | 2005 |
|
RU2387454C2 |
| METHOD OF PREDICTING VASCULAR DISORDERS IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION | 2009 |
|
RU2428105C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| METHOD OF PREDICTING RISK OF DEVELOPING BREAST CANCER IN WOMEN USING MOLECULAR GENETIC DATA | 2023 |
|
RU2809798C1 |
| METHOD FOR PREDICTION OF RISK OF ESSENTIAL HYPERTENSION DEVELOPMENT BASED ON MATRIX METAL PROTEINASE GENES COMBINATIONS | 2016 |
|
RU2624480C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING ESSENTIAL ARTERIAL HYPERTENSION | 2019 |
|
RU2703559C1 |
